Abstract
Childhood tuberculosis (TB) continues to be a neglected disease in areas where limited resources restrict the focus of national TB control programmes to only the most infectious sputum smear-positive cases. However, appreciation that children contribute a significant proportion to the global TB disease burden and suffer severe TB-related morbidity and mortality is growing. The World Health Organization (WHO) published guidelines on the management of paediatric TB in 2006 and child friendly drug formulations have been made available to deserving nations via the Global Drug Facility (GDF) since 2008. These advances also served to emphasize the considerable programmatic barriers that remain in resource- limited settings. This review provides an overview of current treatment practices, presenting the authors personal perspectives on issues related to the treatment of childhood TB, together with a brief synopsis of potential future treatment options.
Keywords: Pediatric tuberculosis, management, treatment, TB, infectious sputum, GDF, current treatment practices, childhood TB, future treatment options, children, bacterial pneumonia, HIV, respiratory disease, first-line antibiotics, endemic areas
Infectious Disorders - Drug Targets
Title: Management of Tuberculosis in Children and New Treatment Options
Volume: 11 Issue: 2
Author(s): B. J. Marais, H. S. Schaaf and P. R. Donald
Affiliation:
Keywords: Pediatric tuberculosis, management, treatment, TB, infectious sputum, GDF, current treatment practices, childhood TB, future treatment options, children, bacterial pneumonia, HIV, respiratory disease, first-line antibiotics, endemic areas
Abstract: Childhood tuberculosis (TB) continues to be a neglected disease in areas where limited resources restrict the focus of national TB control programmes to only the most infectious sputum smear-positive cases. However, appreciation that children contribute a significant proportion to the global TB disease burden and suffer severe TB-related morbidity and mortality is growing. The World Health Organization (WHO) published guidelines on the management of paediatric TB in 2006 and child friendly drug formulations have been made available to deserving nations via the Global Drug Facility (GDF) since 2008. These advances also served to emphasize the considerable programmatic barriers that remain in resource- limited settings. This review provides an overview of current treatment practices, presenting the authors personal perspectives on issues related to the treatment of childhood TB, together with a brief synopsis of potential future treatment options.
Export Options
About this article
Cite this article as:
J. Marais B., S. Schaaf H. and R. Donald P., Management of Tuberculosis in Children and New Treatment Options, Infectious Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187152611795589645
DOI https://dx.doi.org/10.2174/187152611795589645 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antimicrobial Potential of Benzamides and Derived Nanosystems for Controlling in vitro Biofilm Development on Medical Devices
Current Organic Chemistry Tuberculosis and HIV Coinfection–the Challenge in the Prevention, Detection and Treatment of Tuberculosis
Current Bioinformatics Prevention and Management of SARS-CoV-2 Infection Among the Health Care Workers
Coronaviruses Microbial Interactions in Plants: Perspectives and Applications of Proteomics
Current Protein & Peptide Science Aminopyrimidinimino Isatin Analogues: Design and Synthesis of Novel Non- Nucleoside HIV-1 Reverse Transcriptase Inhibitors with Broad- Spectrum Anti-Microbial Properties
Medicinal Chemistry Synthesis, Anticlotting and Antiplatelet Effects of 1,2,3-Triazoles Derivatives
Medicinal Chemistry Recent Advances in Methodologies for the Discovery of Antimycobacterial Drugs
Current Bioactive Compounds Seco-Tetracyclic and Seco-Pentacyclic Triterpenoids from Nature: Phytochemistry, Biological Activity: A Review
Mini-Reviews in Organic Chemistry Current Update on Eosinophilic Lung Diseases and Anti-IL-5 Treatment
Recent Patents on Anti-Infective Drug Discovery The Biotin Biosynthetic Pathway in Mycobacterium tuberculosis is a Validated Target for the Development of Antibacterial Agents
Current Medicinal Chemistry In vitro Anti-Mycobacterial Activities of Various 2-Deoxyuridine, 2- Arabinouridine and 2-Arabinofluoro-2-deoxyuridine Analogues: Synthesis and Biological Studies
Medicinal Chemistry Synthesis and Evaluation of Anti-Tuberculosis and Anti-Cancer Activities of Hydrazones and N-Acylhydrazones by Using Sonochemistry, A New General Procedure
Letters in Drug Design & Discovery Pharmacophore and Docking Based Virtual Screening of Validated Mycobacterium tuberculosis Targets
Combinatorial Chemistry & High Throughput Screening An 8-Year Retrospective Study of Human Visceral Leishmaniasis
Current Clinical Pharmacology Liposomes: Targeted and Controlled Delivery System
Drug Delivery Letters NMDA Pathology and Treatment of Schizophrenia
Current Pharmaceutical Design Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review
Mini-Reviews in Medicinal Chemistry Toxicogenomics to Improve Comprehension of the Mechanisms Underlying Responses of In Vitro and In Vivo Systems to Nanomaterials: A Review
Current Genomics Heterocycles in the Treatment of Neglected Tropical Diseases
Current Medicinal Chemistry Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy